TraceLink unveils EU FMD Express

11 Apr 2018

Purpose-built compliance solution for smaller pharmaceutical companies.

TraceLink has launched EU FMD Express – a cost-effective, simplified solution designed specifically to address the needs of smaller pharmaceutical companies complying with the EU Falsified Medicines Directive (FMD.)

TraceLink unveils EU FMD Express

With far greater resource and budget constraints than their larger counterparts, many small pharmaceutical companies face extreme challenges with serialization, including master data management and data exchange with their CMOs, making it difficult to meet the EU FMD deadline by February 2019.

TraceLink’s EU FMD Express provides these companies with a simple approach to meet EU FMD compliance while controlling costs and minimizing business impact. With over 40,000 users regularly accessing the Life Sciences Cloud system, TraceLink’s EU FMD Express is a complete, easy to use solution that allows smaller manufacturers to comply with EU FMD and integrate with the EU Hub through a single, secure connection, while removing the burden of software maintenance and upgrades, and insulating companies from regulatory changes.

“Due to its size and vast number of companies spread across various countries, Europe is one of the largest and most complex markets, leaving hundreds of small companies grappling with how to achieve EU FMD compliance within the next 11 months,” said Shabbir Dahod, president and CEO, TraceLink. “As the market leader, we feel that is our responsibility to help every company comply, regardless of size, and therefore developed this cost-effective, easy to use offering to streamline the ability for smaller companies to become compliant on time, with no disruption to their business operations. Through our investment in services and support in the EU and unique network architecture to accelerate company on-boarding, TraceLink is the only company positioned to provide such an offering for this market.”

EU FMD Express: key benefits for small pharmaceutical companies

Designed specifically for smaller pharmaceutical companies with simple supply chains, EU FMD Express utilizes purpose-built templates and compliance modules for faster implementation and predictable costs. TraceLink executes the entire deployment, including system configuration and data entry. Every EU FMD Express customer will benefit from the following:
  • Easy to Use and Proven Solution That Is Purpose-Built for Smaller Companies – Enabling portal access for line management systems and CMOs with integration options available; access to TraceLink’s serial number and event repository; and direct integration into the EU Hub.
  • Simplified Deployment, Set-Up and Configuration – TraceLink Services will help EU FMD Express customers define and manage their master data, on-board and train their CMOs, configure the EU compliance module, support for QA testing and validation, and user training.
  • Ongoing Training and Education – All EU FMD Express users will have full access to TraceLink configuration templates for master data and serial number templates. TraceLink also provides an online collaboration workspace for companies to exchange customer configuration documents and full access to TraceLink University for tutorials and e-learning courses.
  • Read More

    Related news

    BIA Separations expands with new upstream processing facility

    BIA Separations expands with new upstream processing facility

    20 Sep 2018

    Provides single source of expertise for scaled production of complex biologics for gene therapy and vaccines.

    Read more 
    Sanofi to refocus two global business units

    Sanofi to refocus two global business units

    19 Sep 2018

    The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.

    Read more 
    Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

    Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

    18 Sep 2018

    China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.

    Read more 
    Recipharm connects to European Hub for serialisation compliance

    Recipharm connects to European Hub for serialisation compliance

    18 Sep 2018

    Connection allows the marketing authorisation holders within the Recipharm Group to continue to supply medicines to patients post the EU FMD implementation date.

    Read more 
    Bosch to unveil new laboratory device for continuous manufacturing

    Bosch to unveil new laboratory device for continuous manufacturing

    18 Sep 2018

    The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production.

    Read more 
    Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

    Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

    17 Sep 2018

    Pall and Aetos to advance the market impact of biosimilars and deliver lower-priced, high-quality options to end users.

    Read more 
    Cambrex expands manufacturing footprint with acquisition

    Cambrex expands manufacturing footprint with acquisition

    16 Sep 2018

    Completed acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.

    Read more 
    NMPA approves fruquintinib capsules for metastatic colorectal cancer

    NMPA approves fruquintinib capsules for metastatic colorectal cancer

    13 Sep 2018

    Fruquintinib - innovative medicine that has not previously been launched in China or internationally - provides a new therapeutic approach for metastatic colorectal cancer patients.

    Read more 
    Aptar Pharma to showcase an industry first

    Aptar Pharma to showcase an industry first

    12 Sep 2018

    PureHale is a new portable drug delivery device designed for upper respiratory care.

    Read more 
    Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

    Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

    11 Sep 2018

    The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.

    Read more